Insilico and EX-vivo immunogenicity analysis of ncats gene therapy test
Ended Awarded Last action
- Contract number
- 75N91023F00009
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,007,301
Award facts
- Contract value 74% obligated
-
- $1,007,301.00 Current, with exercised options
- $1,361,419.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Change Order | $564,711 | |
| Other Administrative Action | $0 | |
| Original award | $442,590 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on July 3, 2023, with a ceiling value of $1,361,419 for in silico and ex vivo immunogenicity analysis of NCATS gene therapy test articles, completing July 2, 2026.
Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis with no set-aside. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center contractor for the National Cancer Institute and National Institutes of Health, providing biomedical research and facilities support.
Service Contract Inventory reporting shows actual government-invoiced activity of $12 thousand and 5 contractor hours in FY2023, followed by $43 thousand, 0.1 FTEs, and 127 contractor hours in FY2024. Derived government-paid hourly rates declined from $2,355.27 per hour in FY2023 to $334.73 per hour in FY2024. The prime self-performed all reported hours with no subcontractors.
Quick answers
Who was awarded contract 75N91023F00009?
75N91023F00009 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on July 3, 2023.
How much is contract 75N91023F00009 worth?
The government has obligated $1,007,301 on 75N91023F00009. Its potential value, with all options, is $1,361,419.
Is contract 75N91023F00009 an order under another contract?
Yes. 75N91023F00009 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00009 competed?
The extent of competition for 75N91023F00009 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award